Collplant Biotechnologies Ltd
NASDAQ: CLGN · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Collplant Biotechnologies Ltd (CLGN) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2012 | — | $-4.46M | — | — | — |
| 2013 | — | $-4.56M | — | — | — |
| 2014 | $0.00 | $-3.64M | — | — | — |
| 2015 | $0.00 | $-4.80M | — | — | — |
| 2016 | $75911.00 | $-7.27M | -196.29% | -9,433.24% | -9,571.91% |
| 2017 | $479917.00 | $-5.80M | 32.85% | -1,244.18% | -1,209.56% |
| 2018 | $4.79M | $-6.25M | 64.99% | -84.91% | -130.50% |
| 2019 | $2.32M | $-11.16M | 18.94% | -329.21% | -481.62% |
| 2020 | $6.14M | $-5.77M | 43.65% | -91.23% | -94.09% |
| 2021 | $15.64M | $237000.00 | 87.18% | 0.42% | 1.52% |
| 2022 | $299000.00 | $-16.93M | -393.65% | -5,718.06% | -5,660.54% |
| 2023 | $10.96M | $-7.02M | 71.78% | -68.55% | -64.05% |
| 2024 | $515000.00 | $-16.61M | -417.09% | -3,349.71% | -3,225.05% |
| 2025 | $2.37M | $-11.49M | 26.32% | -484.31% | -484.56% |
Frequently asked questions
What is Collplant Biotechnologies Ltd's revenue?
Collplant Biotechnologies Ltd's trailing twelve-month revenue is $2.37M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is CLGN?
In its most recent fiscal year, CLGN ran a gross margin of 26.32%, an operating margin of -484.31%, and a net margin of -484.56%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does CLGN generate?
CLGN produced $-9.45M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is CLGN's balance sheet healthy?
CLGN holds $5.95M in cash and equivalents against — in long-term debt, on $6.08M of shareholder equity. That debt is best read against the cash flow the business throws off each year.